<DOC>
	<DOCNO>NCT01149057</DOCNO>
	<brief_summary>This single arm , open-label study evaluate efficacy safety RoActemra/Actemra ( tocilizumab ) patient active , moderate severe rheumatoid arthritis inadequate response non-biologic and/or biologic disease-modifying antirheumatic drug ( DMARDs ) . Patients receive intravenous RoActemra/Actemra dose 8 mg/kg every 4 week . Anticipated time study treatment 96 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Patients With Active Rheumatoid Arthritis Who Have Inadequate Response Current Non-Biologic and/or Biologic DMARDS</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Active moderate severe rheumatoid arthritis Inadequate response &gt; /=3 DMARDs ( nonbiologic and/or biologic ) Current treatment stable dose &gt; /=8 week Etanercept discontinue &gt; /=2 week , Anakinra &gt; /=1 week , Infliximab , Adalimumab , Abatacept , Golimumab , Certolizumab &gt; /=4 week , prior baseline visit . Patients discontinue MabThera/Rituxan Ocrelizumab &gt; /=16 week , must prove Bcell repletion Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow baseline Rheumatic autoimmune disease RA Functional class IV ( American College Rheumatology Classification ) Prior history current inflammatory joint disease RA Oral corticosteroid dose &gt; 10 mg/day prednisone equivalent Positive hepatitis B surface antigen ( HBsAg ) / total hepatitis B core antibody ( HBcAb ) hepatitis C virus ( HCV ) antibody Current history recurrent bacterial , viral , fungal mycobaterial infection History currently active primary secondary immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>